EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Tri iodo thyromine kinetics in eu thyroid graves disease patients who exhibit hyper responsiveness to trh after radio iodine treatment






Clinical Endocrinology 15(4): 417-421

Tri iodo thyromine kinetics in eu thyroid graves disease patients who exhibit hyper responsiveness to trh after radio iodine treatment

A major reduction in T3 [triiodothyronine] was demonstrated previously in clinically hypothyroid patients. This study used non-compartmental (NC) and mono-compartmental (MC) analysis to study 10 patients with Graves' disease who, following treatment with radioactive iodine (RAI), are now clinically euthyroid but who showed hyper-responsiveness to TRH although serum T3 and thyroxine concentrations are within the normal range. T3 production rate (PR), metabolic clearance rate (MRC) and fractional-turnover (K) were all significantly reduced in patients compared with 7 controls (P < 0.01). T3, MCR and PR were consistently higher, and T3 K lower, when calculated by MC, than values calculated by NC analysis. The difference in T3 production rates between patients (mean 16.6 nmol/day) and controls (mean 38.9 nmol/day) raises the question of replacement therapy in patients who are apparently euthyroid but TRH hyper-responsive.


Accession: 006840103



Related references

T3 kinetics in euthyroid Graves' disease patients who exhibit hyper-responsiveness to TRH after radioiodine treatment. Clinical Endocrinology 15(4): 417-421, 1981

Serum thyro globulin in normal subjects and patients with hyper thyroidism due to graves disease effects of tri iodo thyronine iodide iodine 131 and anti thyroid drugs. Clinical Endocrinology 11(6): 585-594, 1979

The stimulation of thyroidal thyroxine to tri iodo thyronine conversion by long acting thyroid stimulator as one of the possible mechanisms for hyper tri iodo thyroninemia in graves disease. Clinical Nuclear Medicineuppl: P38, 1982

The effect of radio iodine treatment on thyroid stimulating antibody in graves disease. Annales d'Endocrinologie 42(3): 45A, 1981

Thyroid function after radio iodine therapy for hyper thyroidism response of thyroxine tri iodo thyronine and thyroid stimulating hormone after stimulation of thyrotropin releasing hormone. Verhandlungen Der Deutschen Gesellschaft Fuer Innere Medizinrt Ii: 1874-1877, 1976

Evaluation of tri iodo thyronine kinetics in normal subjects in hypo thyroid and hyper thyroid patients using specific anti serum for the determination of labeled tri iodo thyronine in plasma/. Journal of Clinical Endocrinology and Metabolism 46(2): 203-214, 1978

Thyroid nodule after radio iodine iodine 131 therapy for graves disease. Kaku Igaku 21(3): 215-219, 1984

Evolution of uptake protein bound iodine 131 protein bound iodine 127 and clinical symptoms after tri iodo thyronine treatment in exophthalmic goiter role of lymphoid system and of long acting thyroid stimulator in graves disease stimulation effect. Annales d'Endocrinologie 29(4): 483-495, 1968

Radio iodine uptake into the thyroid gland and in vitro deiodination of di iodo tyrosine in rats following continued pre treatment with different physiologic compounds of iodine. Acta Biologica et Medica Germanica 21(2): 169-176, 1968

Iodine-131 Graves disease therapy Bayesian individual estimation of the kinetics of iodine thyroid trap. Lun, K C , Degoulet, P , Piemme, T E , Rienhoff, O IFIP (International Federation for Information Processing) World Conference Series on Medical Informatics, Vol 7 Parts 1 and 2 ; MEDINFO 92 : liv+858p (Part 1), xxx+779p (Part 2) 959, 1992